Encysive Pharmaceuticals Inc

Encysive Pharmaceuticals — 2007 UBS Global Life Sciences Conference

21 slides from Encysive Pharmaceuticals's conference presentation, Sep 24, 2007

  1. Slide 1: 2007 UBS Global Life Sciences Conference

    2007 UBS Global Life Sciences Conference September 24, 2007

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

  3. Slide 3: Investment Highlights

    Investment Highlights Two Marketed Products THELIN(r) (sitaxentan sodium) developed by Encysive and is approved in the EU, Canada and Australia THELIN is indicated for the treatment of pulmonary arterial hypertension (PAH) Argatroban was developed by Encysive and marketed by GlaxoSmithKline in the U

  4. Slide 4: Lead Product/Program - THELIN in PAH

    Lead Product/Program - THELIN in PAH Pulmonary Arterial Hypertension (PAH) Rare, life-threatening condition causing high blood pressure in the lungs due to narrowing and stiffening of pulmonary arteries Symptoms include shortness of breath, fatigue, dizzy spells, fainting, chest pain, and swelling o

  5. Slide 5: THELIN is Approved in Markets Generating $450 Million Today

    THELIN is Approved in Markets Generating $450 Million Today THELIN is approved for treatment of PAH in Europe, Canada and Australia Today, we estimate these markets are growing at greater than 30% with projected 2007 ETRA category sales of >$450 million* THELIN is launched in UK, Germany, Ireland, N

  6. Slide 6: European Operations Established

    European Operations Established Encysive headquartered outside London, UK Approximately 35 sales reps when fully launched Sales to date largely from UK and Germany Italy and France launches expected in 4Q '07 2008: Top five EU countries will be selling Thelin

  7. Slide 7: Strong European team

    Strong European team Thierry Plouvier, MD - VP, Europe Organon, Chiesi, Lilly Carl Sterritt, EU Operations United Therapeutics, Europe Phina Deichmann, EU Marketing Chiron Andreas Off - Germany GSK, BMS Oncology Francesco Arcudi - Italy Dompe Eva Begaud - France TKT Stephen Tague - UK Neu-Tec, Gilea

  8. Slide 8: THELIN: Competitive Profile

    THELIN: Competitive Profile Once-daily oral tablet requiring no titration Highly selective, with a high affinity for ETa Only approved selective ETRA for PAH in the EU Rate of liver enzyme elevations similar to placebo Approved for primary PAH and PAH associated with CTD No clinically meaningful int

  9. Slide 9: U.S. Regulatory Status

    U.S. Regulatory Status FDA says THELIN is "Approvable" Agency recommends an additional Phase III trial for marketing clearance Encysive is now moving forward with study STRIDE-5 Working with FDA to finalize a study protocol Details of the study to be announced once protocol discussions are concluded

  10. Slide 10: U.S. PAH Market Will Remain Attractive

    U.S. PAH Market Will Remain Attractive US ETRA market projected to exceed $1.4 billion in 2011* Disease awareness will continue to expand diagnosis ETRAs projected to remain a therapeutic mainstay Encysive believes THELIN can capture a meaningful share of ETRA market in the US *Source: Encysive Phar

  11. Slide 11: Pipeline: Leveraging the Therapeutic Opportunity of ETRAs

    PIPELINE Leveraging the Therapeutic Opportunity of ETRAs Blocking Endothelin has potential in a wide range of cardiovascular diseases

  12. Slide 12: THELIN in Diastolic Heart Failure (DHF)

    THELIN in Diastolic Heart Failure (DHF) Phase 2 trial fully enrolled Approximately 150 DHF patients from 40 centers Randomized, placebo controlled study Primary endpoint: Change in exercise capacity Data expected mid 2008 Positive results sets stage for initiation of pivotal studies

  13. Slide 13: Diastolic Heart Failure (DHF)

    Diastolic Heart Failure (DHF) DHF characterized by the signs and symptoms of chronic heart failure (historically known as CHF with normal ejection rate) Few studies focused only on DHF Large Market Opportunity Estimated 4.4 million patients in North America and Europe* Few treatment options availabl

  14. Slide 14: Next Generation ETRA: TBC3711

    Next Generation ETRA: TBC3711 TBC3711 is Encysive's next generation, highly selective ETRA 100,000 times selective for endothelin A receptor More potent than THELIN High oral bio-availability

  15. Slide 15: Resistant Hypertension (rHTN)

    Resistant Hypertension (rHTN) Defined as persistent blood pressure above 140/90 despite treatment with three anti-hypertensive therapies, including a diuretic Easily identifiable patient population By definition, area of high unmet medical need Large Market Opportunity Estimated 4.5 million existing

  16. Slide 16: Resistant Hypertension Study

    Resistant Hypertension Study Randomized, placebo controlled dose-ranging study Approximately 150 patients Primary endpoint: sitting and standing BPs taken pre-dose and 2 hours post-dose during clinic visits Enrollment ongoing Positive results sets stage for initiation of pivotal studies

  17. Slide 17: Pipeline Chart

    Pipeline Chart PROPRIETARY PRODUCTS THELIN(tm) Oral THELIN(tm) Oral- US CCR9 PC2 Oral* PC3 Intravenous PAH Undisclosed ILD THELIN(tm) Oral Undisclosed Post-surgery PH TBC3711 Oral THELIN(tm) Intravenous TBC3711 Intravenous IBD Undisclosed Undisclosed Resistant HTN Undisclosed PARTNERED PRODUCTS Arga

  18. Slide 18: Financial Highlights

    Financial Highlights Cash, cash equivalents, accrued interest and restricted cash at 6/30/07 Cash, cash equivalents, accrued interest and restricted cash at 6/30/07 $65.0M* 2Q 2007 Financial Snapshot: 2Q 2007 Financial Snapshot: 2Q 2007 Financial Snapshot: Revenues Sales Royalty Income R&D Exp. Sale

  19. Slide 19: Upcoming Milestones

    Upcoming Milestones Commercial milestones Reimbursement and launch of THELIN in Canada, France and Italy - 2H 2007 Clinical milestones Report results from Phase 2 THELIN trial for Diastolic Heart Failure - mid 2008 CCR9 program to enter human testing for Inflammatory Bowel Disease - 2008

  20. Slide 20: Key Personnel

    Key Personnel George W. Cole, President and CEO Joined Encysive is 2005 as COO, promoted to CEO in June 2007 Former President of Altana Pharma U.S, a subsidiary of Germany- based Altana Pharma AG Richard Dixon, Ph.D., Senior VP, Research; CSO Co-founded Encysive in 1989 Former Director and Head of M

  21. Slide 21: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

Encysive Pharmaceuticals — 2007 UBS Global Life Sciences Conference on 6ix